Skip to content
DataLookout
Menu

ALL-CD22-PhNCT07921550

Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

8-week NGS-MRD-negative complete remission (CR_MRD-) rate
Timeframe: up to 8 weeks

Secondary (8)

2-week NGS-MRD-negative CR rate
12-week flow-cytometry MRD-negative CR rate
Event-free survival (EFS)
Overall survival (OS)
Disease-free survival (DFS)
Show 3 moreShow less
Relapse-free survival (RFS)
Cumulative incidence of relapse
Early mortality at 4 weeks and 8 weeks

Arms and interventions

2VIP induction followed by blinatumomab, then pediatric-inspired chemoExperimental

Induction 2VIP: Inotuzumab 1 mg d4 and d11; Vincristine 1.4 mg/m² (max 2 mg) d1,8; Venetoclax ramp 100/200/400 mg d6-14; Prednisone 1 mg/kg/d d1-14. Immunologic consolidation: Blinatumomab 8.75 μg d1-8 then 28 μg d9-28. Subsequent CAMVL / HD-MTX-based early intensification / VDLD delayed intensification / maintenance (female 2.5 y, male 3 y). Optional additional 2VIP or Blinatumomab per protocol

Drugs: Inotuzumab ozogamicin (INO), Venetoclax (VEN), Vincristine, Prednisone

Biologicals: Blinatumomab